Form D · Venture Capital Fund
Novalis LifeSciences Investments II, L.P.
Hampton, NH · CIK 0001890017
Offering snapshot reported Mar 29, 2022 · SEC filing
- Reported sold
- $297M Indefinite offering
- Investors reported
- 51 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 29, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
- Reported investors0 → 51
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 29, 2022 | Amendment | $296,800,000 | No comparison | 51 | SEC filing |
| Oct 26, 2021 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Pooled investment fund
- Exemptions
- 06c, 3C, 3C.7
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-418587
Source: Form D, filed Mar 29, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Marijn E. Dekkers | Executive |
| Paul Meister | Executive |
Issuer details
Industry: Pooled Investment Fund (See others in industry)
Address:
1 Liberty Lane E Suite 112
Hampton, NH, 03842
Hampton, NH, 03842